New Cancer Treatment Available in the United Kingdom


Hellerup, Denmark, September 30, 2013. Azanta A/S, a Danish specialty pharmaceutical company and Haemologic™ Ltd have entered an exclusive agreement to provide Azanta’s products in the United Kingdom. Haemologic, who specializes in compassionate use programs, expects to make the product line available under the MHRA regulation by supplying to fulfill special patient needs.

The portfolio that is now being made available in the United Kingdom consists of Nimoral, a radiosensitizer that enhances the effect of radiotherapy in head and neck cancer patients. Further, Zybrestat, which is a vascular disrupting agent for use against anaplastic thyroid cancer, is included in the agreement. Finally, Angusta, a new 25 mcg formulation of the prostaglandin E1 analogue misoprostol used for cervical ripening, is included in the agreement.

Dr. Claus Møller, Chief Executive Officer of Azanta, commented: “The agreement with Haemologic allows us to make our products available in the UK, where we have experienced a substantial interest for these novel treatments. We are pleased to sign the agreement with Haemologic™, whom we believe will be an excellent partner for Azanta in this special pharmaceutical niche.”

Under the terms of the agreement, Haemologic will make the products available under compassionate use programs.

— ooo —

Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Zybrestat, a vascular disrupting agent used for anaplastic thyroid cancer. In addition, Azanta A/S has a portfolio of low risk development projects for commercialization within the near future.

For further information, please visit

Haemologi is a company run by personnel that have a wealth of experience in secondary care specialist medicine. Ms Lisa Mitchell, who has a substantial track record in pharmaceuticals with Pharmacosmos & Vitaline Pharmaceuticals, Ferring and Pharmacia heads the organisation. Haemologic is dedicated to making specialist pharmaceutical products available as named patient medicine and under compassionate use programs.

Contact Azanta:
Claus Møller
Tel: + 45 – 70 25 95 45
Fax: + 45 – 70 25 95 46

Contact Haemologic:
Lisa Mitchell
Tel : + 44 (0) 7767 820883

For further interest in Azanta’s specialty pharma products or investigational cancer products, please contact your local representative or Azanta’s head office.

Find representative